The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and preliminary efficacy of CTx001 as a potential one-time treatment for GA Opti-GAIN builds on insights from i-GAIN, a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...
Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback